TNFSF10 and neoplasm: There are other possibilities to “arm” expanded NK cells, e.g., (i) with activating receptors that enhance their natural anti-tumor capacity; (ii) with chimeric antigen receptors (CAR) that can redirect them toward specific tumor targets (45); or (iii) with death receptor ligands such as a glycosylated form of TNF-related apoptosis-inducing ligand (TRAIL) fusion protein (69).